Quinestrol

Synonyms: 炔雌醚; W-3566
Quinestrol(W-3566)是一种口服有效的人工合成雌激素化合物,可作用于CYP3A4、CYP1A2和GnRH,通过干扰GnRH释放破坏下丘脑-垂体-卵巢轴,下调促卵泡激素β和促黄体生成素β的基因表达,诱发氧化应激,损伤生殖器官,降低精子密度与活力并升高精子畸形率,同时改变睾酮、促黄体生成素、雌二醇和孕酮等性激素水平,因此可用于生殖功能调控相关研究。
产品编号: MS-M53318 纯度: 99.19% CAS No.: 152-43-2 分子式: C25H32O2 分子量: 364.52
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
25mg
询价
3-5 天
50mg
询价
3-5 天
100mg
询价
询价
200mg
询价
询价

产品描述

Quinestrol(W-3566)是一种口服有效的人工合成雌激素化合物,可作用于CYP3A4、CYP1A2和GnRH,通过干扰GnRH释放破坏下丘脑-垂体-卵巢轴,下调促卵泡激素β和促黄体生成素β的基因表达,诱发氧化应激,损伤生殖器官,降低精子密度与活力并升高精子畸形率,同时改变睾酮、促黄体生成素、雌二醇和孕酮等性激素水平,因此可用于生殖功能调控相关研究。

生物实验数据

生物活性 Quinestrol (W-3566) is an orally active synthetic estrogenic compound that acts on CYP3A4, CYP1A2, and GnRH; it disrupts the hypothalamic-pituitary-ovarian axis by interfering with GnRH release, downregulates the gene expression of follicle-stimulating hormone β and luteinizing hormone β, induces oxidative stress, damages reproductive organs, decreases sperm density and motility while increasing sperm abnormality rate, and alters sex hormone levels including testosterone, luteinizing hormone, estradiol, and progesterone, and is therefore applicable to research related to reproductive function regulation.
IC50 & Target

CYP1A2

 

CYP3A4

 

体内研究
(In Vivo)

Quinestrol (50 mg/kg;口服;每日一次;连续 4 天) 可提高雄性瑞士小鼠求偶超声发声速率及谐波音节占比,使其对雌性瑞士小鼠更具吸引力,但不改变音节结构及雄性小鼠的公开交配行为。
Quinestrol (4 mg/kg;口服;每日 1 次,连续给药 3 天,25 天后重复给药 3 天) 可有效改变雌性蒙古沙鼠生殖器官重量、类固醇激素水平以及肝和肾中 CYP3A4/CYP1A2 的总含量;多数代谢相关效应在给药后 15 天恢复,但子宫重量和血清孕酮水平仍保持升高状态。
Quinestrol (200 μg;口服;每 15 天 1 次;持续至 210 天):对雌性大鼠长期口服给药后,可在所有时间点显著增加肝脏重量;在 38-42 天和 218-222 天降低血清胆固醇;仅在 38-42 天降低胆汁流量、血清 BSP 浓度及胆汁 BSP 浓度 (上述后几种效应在 30 天后趋于对照组水平),而对关键肝酶或胆红素水平无影响。
Quinestrol (1.0-5.0 mg/kg;口服;每日 1 次;连续 3 天) 可呈剂量依赖性抑制雄性小鼠的生殖能力,其中较高剂量 (5.0 mg/kg) 会在第 10 天时使生殖器官重量、精子密度和睾酮水平出现更显著的降低,而上述作用在第 30 天时可部分恢复。
Quinestrol (1.0-5.0 mg/kg 联合 0.4-2.0 mg/kg Ketoconazole (MS-X73232);口服;两次灌胃间隔 30 分钟,每日 1 次,连续给药 3 天) 与 Ketoconazole 联合给药可增强雄性 Mus musculus 的生殖抑制作用。

Animal Model: Swiss mice (male, 4-6 months old, 45-60 g; female, 4-6 months old, 40-55 g)
Dosage: 50 mg/kg
Administration: p.o.; daily; 4 days
Result: Reduced body weight from 54.13 g to 51.44 g one week after administration.
Elevated syllable rate to 82.76 syllables/min in early heterosexual interactions, far above the control level.
Raised the proportion of harmonic syllables in ultrasonic vocalizations to 16.1%, compared with 3.55% in the control group.
Increased female approaching frequency to 13.27 times within 30 minutes, notably higher than the control value of 5.00 times.
Displayed no obvious distinctions from controls in vocal parameters and major mating-related behaviors.
Animal Model: Meriones unguiculatus (female, virgin, 3-4 months old, 60.6 g)
Dosage: 4 mg/kg
Administration: p.o.; daily for 3 days, repeated 25 days later for another 3 days
Result: Raised uterine weight progressively by 147%, 180% and 355% over 5, 10 and 15 days post the second dosing.
Exerted no influence on ovarian weight.
Elevated liver weight at day 5, which gradually normalized by day 15.
Elevated kidney weight at days 5 and 10, which gradually normalized by day 15.
Elevated serum progesterone by 1012%, 816% and 768% across three time points, remaining above baseline at day 15.
Elevated serum estradiol at days 5 and 10, which returned to normal at day 15.
Upregulated total hepatic CYP3A4 and CYP1A2 content at day 5, followed by full recovery later.
Upregulated total renal CYP3A4 and CYP1A2 content at days 5 and 10, followed by full recovery at day 15.
Produced no changes in average CYP3A4 and CYP1A2 content in liver and kidney throughout the experiment.
Triggered no obvious alterations to body mass.
Animal Model: Inbred female rats (adult, 150-280 g)
Dosage: 200 μg
Administration: p.o.; every 15 days; up to 210 days
Result: Elevated relative liver weight at all monitored time points with distinct statistical differences.
Lowered serum cholesterol notably at 38-42 days and 218-222 days.
Suppressed bile flow significantly only during the 38-42 day period.
Decreased serum BSP content significantly at 38-42 days.
Diminished bile BSP content significantly at 38-42 days.
Exerted no obvious effects on multiple serum enzymes and bilirubin levels throughout the trial.
Induced no histological lesions in liver tissues.
Rendered altered bile flow and BSP contents gradually return to baseline after 30 days of administration.
Animal Model: Kunming mice (healthy adult male)
Dosage: 1.0 mg/kg; 5.0 mg/kg
Administration: p.o.; once daily; 3 consecutive days
Result: Reduced seminal vesicle weight by 32.17%, sperm density by 18.00%, serum testosterone levels by 73.25%, increased liver weight by 11.63%, and spleen weight by 23.85% compared to control at 10 days with 1.0 mg/kg.
Reduced epididymal weight by 21.97%, seminal vesicle weight by 63.22%, sperm density by 30.85%, serum testosterone levels by 75.09%, increased liver weight by 49.81% (significant, p<0.05), and spleen weight by 25.45% compared to control at 10 days with 5.0 mg/kg.
Reduced seminal vesicle weight by 11.18%, serum testosterone levels by 56.83%, increased liver weight by 9.74% compared to control at 30 days with 1.0 mg/kg.
Reduced seminal vesicle weight by 26.48%, serum testosterone levels by 40.59%, increased liver weight by 18.50%, and spleen weight significantly compared to other groups (p<0.05) compared to control at 30 days with 5.0 mg/kg.
Animal Model: Kunming mice (healthy adult male)
Dosage: 1.0 mg/kg quinestrol + 0.4 mg/kg ketoconazole; 1.0 mg/kg quinestrol + 2.0 mg/kg ketoconazole; 5.0 mg/kg quinestrol + 0.4 mg/kg ketoconazole
Administration: p.o.; sequential gavages 30 minutes apart, once daily; 3 consecutive days
Result: Lowered reproductive organ weights, sperm parameters and testosterone, elevated spleen weight and CYP3A4 levels at 10 days (1.0 mg/kg quinestrol + 0.4 mg/kg ketoconazole).
Reduced reproductive indicators and LH, slightly raised visceral weights; intestinal CYP3A4 decreased while hepatic CYP3A4 increased at 10 days (1.0 mg/kg quinestrol + 2.0 mg/kg ketoconazole).
Decreased reproductive indexes and LH, increased liver and spleen weight; intestinal CYP3A4 declined and hepatic CYP3A4 rose at 10 days (5.0 mg/kg quinestrol + 0.4 mg/kg ketoconazole).
Reduced reproductive parameters and hormones, slightly increased liver weight; CYP3A4 levels dropped at 30 days (1.0 mg/kg quinestrol + 0.4 mg/kg ketoconazole).
Decreased visceral weight and serum hormones; intestinal and hepatic CYP3A4 were downregulated at 30 days (1.0 mg/kg quinestrol + 2.0 mg/kg ketoconazole).
Reduced visceral and reproductive weights as well as hormones; overall CYP3A4 expression decreased at 30 days (5.0 mg/kg quinestrol + 0.4 mg/kg ketoconazole).
性状 固体
颜色 White to off-white

化学信息

分子量 364.52
分子式 C25H32O2
CAS No. 152-43-2
别名 炔雌醚; W-3566

储存&溶解度

储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 2 years
-20°C 1 year
运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 250 mg/mL (685.83 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

Ethanol 中的溶解度 : 25 mg/mL (68.58 mM; 超声助溶)

可选溶剂浓度1 mg5 mg10 mg25 mg
Ethanol / DMSO1 mM2.7433 mL13.7167 mL27.4333 mL68.5833 mL
5 mM0.5487 mL2.7433 mL5.4867 mL13.7167 mL
10 mM0.2743 mL1.3717 mL2.7433 mL6.8583 mL
15 mM0.1829 mL0.9144 mL1.8289 mL4.5722 mL
20 mM0.1372 mL0.6858 mL1.3717 mL3.4292 mL
25 mM0.1097 mL0.5487 mL1.0973 mL2.7433 mL
30 mM0.0914 mL0.4572 mL0.9144 mL2.2861 mL
40 mM0.0686 mL0.3429 mL0.6858 mL1.7146 mL
50 mM0.0549 mL0.2743 mL0.5487 mL1.3717 mL
60 mM0.0457 mL0.2286 mL0.4572 mL1.1431 mL
DMSO80 mM0.0343 mL0.1715 mL0.3429 mL0.8573 mL
100 mM0.0274 mL0.1372 mL0.2743 mL0.6858 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 2 years; -20°C, 1 year。-80°C储存时,请在2年内使用, -20°C储存时,请在1年内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础